ClinicalTrials.gg
CompletedNCT01476904Updated Feb 13, 2017

Safety Study in Adolescent and Adult Patients With Asthma

A Phase 3 interventional study of Placebo and Primatene Mist in Asthma, sponsored by Amphastar Pharmaceuticals, Inc.. Completed at 27 sites in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-02-13.

Sponsored by Amphastar Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Asthma by Amphastar Pharmaceuticals, Inc. — none open to participants now, none under way, none of them phase 3. Asthma · Amphastar Pharmaceuticals, Inc..

Enrollment
3rd of 18
208 · median 25
Started
2011
with 2 others
Phase 3
7 of 18
none open now
Registered
12th of 18
by date

Among the 18 studies in Asthma by Amphastar Pharmaceuticals, Inc., this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is one of 7 in phase 3, and was the 12th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 18 studies in Asthma by Amphastar Pharmaceuticals, Inc. is open now. The open studies under Asthma, anywhere →

Where they have run

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Asthma by Amphastar Pharmaceuticals, Inc. as a file.
02

Study summary

E004-C2 is a continuation of E004-C for safety evaluations with additional 3 months to be able to assess the 6-month safety profile for E004 (epinephrine inhalation) versus placebo in a double-blinded manner.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Bronchial Asthma
  • Shortness of breath
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Only subjects who have successfully completed the E004-C study within the last 135 days or those who are actively enrolled in the current study E004-C at the time of the study extension initiation
  • Male and female asthma patients aged 12 - 75 years
  • Patients with documented asthma, requiring inhaled epinephrine or beta 2-agonist treatment
  • No significant changes in asthma therapy and no asthma-related hospitalization or emergency visits, within 4 weeks prior to Screening
  • Demonstrating satisfactory techniques in the use of metered-dose inhaler and a hand held peak expiratory flow meter
  • Female patients of must be non-pregnant and non-lactating at Screening and throughout the study, and must use an acceptable method of during the study

Exclusion criteria

Exclusion Criteria:

  • A smoking history of 10-pack years, or having smoked within 12 months of screening
  • Any current or past medical conditions that, per investigator discretion, might significantly affect responses to the study drugs, other than asthma
  • Concurrent diseases
  • Known intolerance or to any component of the study drugs
  • Recent infection of the respiratory tract, before screening
  • Use of prohibited medications
  • Having been on other drug/device studies in the last 30 days prior to screening
  • Known or highly suspected substance abuse
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    Arm T

    Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of epinephrine inhalation, QID, with 4-6 hr intervals

    Drug: Epinephrine inhalation

  • Placebo comparator
    Arm P

    Arm P is a placebo comparator consisting of 2× 0 mcg of placebo inhalations, QID, with 4-6 hr intervals

    Drug: Placebo

  • Active comparator
    Arm A

    Arm A is an active comparator, Primatene Mist, consisting of 2× 220 mcg/inhalation, QID, with 4-6 hr intervals

    Drug: Primatene Mist

Interventions

  • DrugPlacebo

    0 mcg/inhalation, 2 inhalations QID

  • 220 mcg/inhalation, 2 inhalations QID

  • DrugEpinephrine inhalation

    125 mcg/inhalation, 2 inhalations QID

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Recording of all adverse events experienced during the course of the study

    Time frame: up to 12 weeks

Secondary outcomes

  1. Change in 12 lead ECG including QT/QTc analysis

    A 12-lead ECG (routine and QT/QTc) will be measured and recorded, provided that dosing of study drug has been performed greater than 1 hour prior to conducting the measurements.

    Time frame: Study visit 4, 8 and 12, greater than one hour after last dose

  2. Asthma Exacerbations

    Review use of resuce inhaler for treatment of asthma exacrbations occuring between doses of study medication.

    Time frame: up to 12 weeks

07

Study locations

27 sites
  • Amphastar Site 0006
    Costa Mesa, California 92626, United States
  • Amphastar Site 0005
    Los Angeles, California 90048, United States
  • Amphastar Site 0004
    Orange, California 92868, United States
  • Amphastar Site 0001
    San Jose, California 95117, United States
  • Amphastar Site 0003
    Stockton, California 95207, United States
  • Amphastar Site 0008
    Denver, Colorado 80230, United States
  • Amphastar Site 0009
    Wheat Ridge, Colorado 80033, United States
  • Amphastar Site 0011
    Iowa City, Iowa 52240, United States
  • Amphastar Site 0013
    North Dartmouth, Massachusetts 02747, United States
  • Amphastar Site 0014
    Minneapolis, Minnesota 55402, United States
  • Amphastar Site 0015
    Plymouth, Minnesota 55441, United States
  • Amphastar Site 0016
    St. Louis, Missouri 63141, United States
  • Amphastar Site 0017
    Bozeman, Montana 59718, United States
  • Amphastar Site 0019
    Bellevue, Nebraska 68123, United States
  • Amphastar Site 0020
    Skillman, New Jersey 08558, United States
  • Amphastar Site 0018
    Raleigh, North Carolina 27607, United States
  • Amphastar Site 0021
    Cincinnati, Ohio 45242, United States
  • Amphastar Site 0024
    Ashland, Oregon 97520, United States
  • Amphastar Site 0022
    Eugene, Oregon 97401, United States
  • Amphastar Site 0023
    Lake Oswego, Oregon 97035, United States
  • Amphastar Site 0025
    Medford, Oregon 97504, United States
  • Amphastar Site 0026
    Portland, Oregon 97202, United States
  • Amphastar Site 0029
    North Charleston, South Carolina 29406, United States
  • Amphastar Site 0031
    El Paso, Texas 79903, United States
  • Amphastar Site 0030
    New Braunfels, Texas 78130, United States
  • Amphastar Site 0033
    Richmond, Virginia 23229, United States
  • Amphastar Site 0034
    Seattle, Washington 98105, United States
08

References and documents

Publications

  • Pinnas JL, Schachtel BP, Chen TM, Roseberry HR, Thoden WR. Inhaled epinephrine and oral theophylline-ephedrine in the treatment of asthma. J Clin Pharmacol. 1991 Mar;31(3):243-7. doi: 10.1002/j.1552-4604.1991.tb04969.x. PubMed 2019665 ↗
  • Hendeles L, Marshik PL, Ahrens R, Kifle Y, Shuster J. Response to nonprescription epinephrine inhaler during nocturnal asthma. Ann Allergy Asthma Immunol. 2005 Dec;95(6):530-4. doi: 10.1016/S1081-1206(10)61014-9. PubMed 16400891 ↗
  • Warren JB, Doble N, Dalton N, Ewan PW. Systemic absorption of inhaled epinephrine. Clin Pharmacol Ther. 1986 Dec;40(6):673-8. doi: 10.1038/clpt.1986.243. PubMed 3780129 ↗
  • Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000 Jun;94 Suppl B:S3-9. PubMed 10919679 ↗
  • Simons FE, Gu X, Johnston LM, Simons KJ. Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis? Pediatrics. 2000 Nov;106(5):1040-4. doi: 10.1542/peds.106.5.1040. PubMed 11061773 ↗
  • Dickinson BD, Altman RD, Deitchman SD, Champion HC. Safety of over-the-counter inhalers for asthma: report of the council on scientific affairs. Chest. 2000 Aug;118(2):522-6. doi: 10.1378/chest.118.2.522. PubMed 10936150 ↗
  • Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999 Jan;159(1):179-87. doi: 10.1164/ajrccm.159.1.9712108. PubMed 9872837 ↗
  • Kerwin EM, Tashkin DP, Korenblat PE, Greos LS, Pearlman DS, Bensch GW, Miller SD, Marrs T, Luo MZ, Zhang JY. Long-term safety and efficacy studies of epinephrine HFA metered-dose inhaler (Primatene(R) Mist): a two-stage randomized controlled trial. J Asthma. 2021 May;58(5):633-644. doi: 10.1080/02770903.2020.1713147. Epub 2020 Jan 20. PubMed 31959019 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Apr 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2011
First posted
Nov 22, 2011
Start
Nov 2011
Primary completionActual
Apr 2012
CompletionActual
Jul 2012
Results delay requested
Feb 11, 2016
Last update
Feb 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01476904
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Nov 22, 2011
Start date
Nov 2011
Primary completion
Apr 2012
Completion
Jul 2012
Last update
Feb 13, 2017

Study contacts

Safety Monitor
study director · Amphastar Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion